Nigeria’s pharmaceutical manufacturing industry faces mounting challenges from dependence on imported raw materials, low factory capacity utilisation and high production costs, the Pan-African Manufacturers Association (PAMA) has warned.
The association said the country’s ambition to reduce dependence on imported medicines would remain difficult to achieve without addressing structural weaknesses across the value chain and creating an environment that enables local manufacturers to produce competitively.
PAMA’s Secretary-General, Segun Ajayi-Kadir, said the challenges confronting Nigeria reflected wider weaknesses in Africa’s pharmaceutical industry, where local manufacturing remains concentrated in a few countries and production depends heavily on imported inputs.
According to the United Nations Conference on Trade and Development (UNCTAD), more than 70 per cent of medicines consumed across Africa in 2025 were imported, especially from Asia.
The World Health Organisation (WHO) estimates that African countries import between 70 and 100 per cent of their medicines and other medical products, while about 99 per cent of vaccines consumed are imported.
The dependence extends beyond finished medicines to active pharmaceutical ingredients (APIs), essential components used in drug production and other manufacturing inputs.
Ajayi-Kadir noted that although pharmaceutical production takes place in about half of African countries, manufacturing capacity remains concentrated in a handful of markets. Eight countries account for 85 per cent of the continent’s approximately 690 pharmaceutical plants, while 11 countries with local production have fewer than five factories each, he noted.
He said the concentration of manufacturing capacity and dependence on imported inputs exposed the weaknesses of the continent’s pharmaceutical industrial base.
Nigeria and other African manufacturers, particularly those involved in drug formulation and packaging, still rely substantially on foreign suppliers for APIs and excipients.
China remains a major global producer of APIs, while India is a leading supplier of finished pharmaceutical products to African countries.
This dependence, he said, exposed local manufacturers to foreign exchange (FX) challenges, international supply disruptions and rising input costs, undermining their ability to compete with imported medicines.
Another major challenge, he added, was the underutilisation of existing manufacturing facilities.
Ajayi-Kadir said pharmaceutical manufacturing required significant investment in specialised equipment, quality-control systems, skilled personnel, regulatory compliance and reliable utilities. Such investments, he noted, could become commercially viable only when factories operated at higher capacity and served sufficiently large markets.
However, evidence cited by UNCTAD indicates that some tablets, capsules and creams manufactured in Nigeria and Ethiopia could be about 15 per cent cheaper than equivalent products imported from India under specified conditions.
The finding challenges the perception that locally manufactured medicines are necessarily more expensive. Instead, it suggests that low production volumes and inefficient capacity utilisation are among the factors undermining the competitiveness of domestic manufacturers.
Ajayi-Kadir also identified government procurement as critical to expanding local production. He said fragmented purchasing, short procurement cycles and unpredictable orders made it difficult for manufacturers to plan production, expand facilities and commit capital to new investments.
Long-term procurement arrangements and pooled purchasing across African countries, he argued, would provide manufacturers with greater certainty about demand, encourage investment and enable factories to operate closer to their installed capacity.
He further highlighted the limitations of fragmented national markets, noting that differences in regulatory requirements, procurement arrangements and trade barriers restricted manufacturers’ access to customers across Africa.
Regional integration, he said, would allow countries to develop complementary manufacturing capabilities rather than attempting to produce every category of medicine independently.
He said the African Medicines Agency (AMA) was expected to support the process through regulatory cooperation and harmonisation. In May 2026, the agency and WHO signed a framework to advance regulatory harmonisation, convergence and reliance across the continent.
Decrying weak investment in the industry, Ajayi-Kadir cited UNCTAD data estimating that Africa accounts for only about five per cent of global greenfield foreign investment in pharmaceutical manufacturing, despite the market’s growth potential.
He said improving investment in Nigeria’s pharmaceutical industry required reliable infrastructure, better access to foreign exchange, industrial financing, regulatory predictability, skilled personnel and stronger intellectual property protection.
Cautioning against blanket import-substitution policies that ignore the financial and technological requirements of different pharmaceutical products, he advocated a selective approach to developing the value chain. This, he said, should prioritise products for which Nigeria has existing manufacturing capabilities, sufficient demand and the potential to achieve competitive production volumes.
“More capital-intensive segments, particularly API and vaccine manufacturing, would require substantial investment, advanced technical capabilities and coordinated regional demand to become commercially sustainable,” he said.
He stressed PAMA’s commitment to working with governments, regulatory authorities and development institutions to strengthen pharmaceutical manufacturing, attract investment and develop regional production capabilities.